Safety of Duavent Nebulization in Pregnancy

Introduction to Safety Concerns

• The American College of Allergy and Clinical Immunology suggests that the safety data for bronchodilators during pregnancy applies to women with asthma or other respiratory conditions, where the benefits of treatment outweigh the risks 1, 2

Potential Maternal Side Effects

• The use of salbutamol in pregnant women can cause maternal tachycardia, palpitations, and potential arrhythmias, as well as metabolic disturbances such as hyperglycemia, which can lead to neonatal hypoglycemia 2
• Salbutamol can also cause tremor, nervousness, and headache, which are common beta-agonist effects 1
• Hypokalemia can occur with excessive dosing of salbutamol 2

Fetal Considerations

• Fetal tachycardia can occur from maternal salbutamol absorption, particularly with systemic administration 2
• Neonatal hypoglycemia can occur secondary to maternal hyperglycemia during drug exposure 2

Pregnancy Safety Classification

• The Australian TGA classifies salbutamol as Category A, with reassuring safety data, but this applies to therapeutic use in asthmatic patients 1, 2

Dose-Dependent Risks

• Doubling the standard nebulized dose of salbutamol and ipratropium amplifies the risks without providing any benefit to someone without bronchospasm 2
• Systemic absorption from nebulization is higher than from metered-dose inhalers, increasing the likelihood of adverse effects 2

Clinical Recommendations

• The American College of Allergy and Clinical Immunology recommends that Duavent should not be administered to a non-asthmatic pregnant woman, as there is no medical justification 2
• If accidentally administered, monitoring is recommended for maternal heart rate and rhythm, blood glucose levels, and fetal heart rate 2